HUTCHMED (China) (HCM) Current Deferred Revenue (2016 - 2025)

HUTCHMED (China) has reported Current Deferred Revenue over the past 10 years, most recently at $31.4 million for Q4 2025.

  • Quarterly Current Deferred Revenue fell 37.26% to $31.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.4 million through Dec 2025, down 37.26% year-over-year, with the annual reading at $31.4 million for FY2025, 37.26% down from the prior year.
  • Current Deferred Revenue was $31.4 million for Q4 2025 at HUTCHMED (China), down from $50.1 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $57.6 million in Q4 2023 and troughed at $13.3 million in Q4 2022.
  • The 4-year median for Current Deferred Revenue is $40.7 million (2024), against an average of $38.1 million.
  • Year-over-year, Current Deferred Revenue soared 331.85% in 2023 and then crashed 37.26% in 2025.
  • A 4-year view of Current Deferred Revenue shows it stood at $13.3 million in 2022, then soared by 331.85% to $57.6 million in 2023, then fell by 13.13% to $50.1 million in 2024, then tumbled by 37.26% to $31.4 million in 2025.
  • Per Business Quant, the three most recent readings for HCM's Current Deferred Revenue are $31.4 million (Q4 2025), $50.1 million (Q4 2024), and $57.6 million (Q4 2023).